Hydrochloric Acid

Hydrochloric Acid

SCHEMBL8954790

CC1(N(CC(=O)O)C(=O)[C@@](N)(Cc2cccc(C(=N)N)c2)S(=O)(=O)c2ccc3ccccc3c2)CCCCN1.Cl

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ KLKB1 known ✓ P03952 1/20 0.38
▸ F10 P00742 11/20 0.40
▸ F2 P00734 3/20 0.40
▸ PRSS1 P07477 2/20 0.40
▸ PLG P00747 9/20 0.39
▸ PLAU P00749 2/20 0.39
▸ HPN P05981 2/20 0.38
▸ F12 P00748 1/20 0.38
▸ PROC P04070 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8954736 0.99 F10 (0.40) F10F2PRSS1PLGPLAU
Hydrochloric Acid SCHEMBL9663503 0.93 F10 (0.41) F10F2PRSS1PLGPLAU
Iodide SCHEMBL8954824 0.90 F10 (0.38) F10F2PRSS1PLGPLAU
SCHEMBL8954860 0.89 F10 (0.41) F10F2PRSS1PLGPLAU
SCHEMBL8954791 0.79 ABCB1 (0.34) —
SCHEMBL8954757 0.77 KAT6A (0.35) —
SCHEMBL8954673 0.74 F10 (0.43) F10F2PRSS1PLGPLAU
SCHEMBL8954760 0.74 F10 (0.48) F10F2PRSS1PLGPLAU
Bicarbonate SCHEMBL9665131 0.73 F10 (0.57) F10F2PRSS1PLGPLAU
SCHEMBL8954743 0.70 F10 (0.40) F10F2PRSS1PLGPLAU

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0373512-B1 (-)-2-PYRAZOLINE COMPOUND, OPTICAL RESOLUTION OF THE SAME, AND THERAPEUTIC AGENT FOR CEREBROVASCULAR DISORDERS CONTAINING THE SAME AS EFFECTIVE INGREDIENT MITSUI TOATSU CHEMICALS, Inc. (JP) 1992-04-08 — — EP claimed
EP-0373512-A1 (-)-2-pyrazoline compound, optical resolution of the same, and therapeutic agent for cerebrovascular disorders containing the same as effective ingredient MITSUI TOATSU CHEMICALS, Inc. (JP) 1990-06-20 — — EP claimed
US-5518735-A ANTICOAGULANTS ADMINISTERED BY MOUTH PENTAPHARM AG (CH) 1996-05-21 — — US disclosed
EP-0511347-A1 META-SUBSTITUTED PHENYL ALANINE DERIVATIVES Pentapharm A.G. (CH) 1992-11-04 — — EP disclosed
WO-1992008709-A1 META-SUBSTITUTED PHENYL ALANINE DERIVATIVES PENTAPHARM AG (CH) 1992-05-29 — — WO disclosed
EP-0373512-B1 (-)-2-PYRAZOLINE COMPOUND, OPTICAL RESOLUTION OF THE SAME, AND THERAPEUTIC AGENT FOR CEREBROVASCULAR DISORDERS CONTAINING THE SAME AS EFFECTIVE INGREDIENT MITSUI TOATSU CHEMICALS, Inc. (JP) 1992-04-08 — — EP disclosed
US-5089622-A (-)-2-PYRAZOLINE COMPOUNDS AND THERAPEUTIC AGENT FOR CEREBROVASCULAR DISORDERS CONTAINING THE SAME AS EFFECTIVE INGREDIENT MITSUI TOATSU CHEMICALS INCORPORATED (JP) 1992-02-18 — — US disclosed
US-5075449-A Using compound containing sulfonate group MITSUI TOATSU CHEMICALS, INC. (JP) 1991-12-24 — — US disclosed
EP-0373512-A1 (-)-2-pyrazoline compound, optical resolution of the same, and therapeutic agent for cerebrovascular disorders containing the same as effective ingredient MITSUI TOATSU CHEMICALS, Inc. (JP) 1990-06-20 — — EP disclosed
Send feedback